The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Combinatorial patterns of somatic gene mutations in cancer
Abstract
Cancer is a complex process in which the abnormalities of many genes appear to be involved. The combinatorial patterns of gene mutations may reveal the functional relations between genes and pathways in tumorigenesis as well as identify targets for treatment. We examined the patterns of somatic mutations of cancers from Catalog of Somatic Mutations in Cancer (COSMIC), a large‐scale database curated by the Wellcome Trust Sanger Institute. The frequently mutated genes are well‐known oncogenes and tumor suppressors that are involved in generic processes of cell‐cycle control, signal transduction, and stress responses. These “signatures” of gene mutations are heterogeneous when the cancers from different tissues are compared. Mutations in genes functioning in different pathways can occur in the same cancer ( i.e. , co‐occur), whereas those in genes functioning in the same pathway are rarely mutated in the same sample. This observation supports the view of tumorigenesis as derived from a process like Darwinian evolution. However, certain combinatorial mutational patterns violate these simple rules and demonstrate tissue‐specific variations. For instance, mutations of genes in the Ras and Wnt pathways tend to co‐occur in the large intestine but are mutually exclusive in cancers of the pancreas. The relationships between mutations in different samples of a cancer can also reveal the temporal orders of mutational events. In addition, the observed mutational patterns suggest candidates of new cosequencing targets that can either reveal novel patterns or validate the predictions deduced from existing patterns. These combinatorial mutational patterns provide guiding information for the ongoing cancer genome projects.—Yeang, C‐H., McCormick, F., Levine, A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 22, 2605–2622 (2008)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several KRAS alleles had reduced comutation with NRAS and BRAF, and increased comutation with APC and PIK3CA”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [48]
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Self-citationGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“The TP53 pathway responds to a variety of stress signals and controls major stress response processes including apoptosis, cell cycle arrest, and senescence (38, 39 ).”
Self-citationBarbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,021
Hirsch, F. R., Varella‐Garcia, M., Bunn, P. A., Maria, M. V. D., Veve, R., Bremnes, R. M., Barón, A. E., Zeng, C., & Franklin, W. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.069 · Cited by 1,476
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/bj3510289 · Cited by 1,443
Flagged first, then by citations
Cited by
Sorted by citations
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Maftools: efficient and comprehensive analysis of somatic variants in cancerPreprint
Mayakonda, A., Lin, D., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 5,005
Leiserson, M. D. M., Vandin, F., Wu, H.-T., Dobson, J. R., Eldridge, J. V., Thomas, J. L., Papoutsaki, A., Kim, Y., Niu, B., McLellan, M. D., et al. (2014) · Nature Genetics · doi:10.1038/ng.3168 · Cited by 922
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
MacConaill, L. E., Campbell, C. D., Kehoe, S. M., Bass, A. J., Hatton, C., Niu, L., Davis, M., Yao, K., Hanna, M., Mondal, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007887 · Cited by 436
De Novo Discovery of Mutated Driver Pathways in CancerPreprint
Vandin, F., Upfal, E., & Raphael, B. J. (2011) · Genome Research · doi:10.1007/978-3-642-20036-6_44 · Cited by 437
Metadata
- Authors
- Yeang, C.-H., McCormick, F., & Levine, A.
- Affiliations
- Institute for Advanced Study (US)
- University of California, San Francisco (US)
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-04-23
- Volume
- 22
- Issue
- 8
- Pages
- 2605-2622
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2126172213
- Cited by
- 251
- References
- 54
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 11 · 2023: 9 · 2022: 13 · 2021: 14 · 2020: 15 · 2019: 23 · 2018: 15 · 2017: 18 · 2016: 22 · 2015: 24 · 2014: 23 · 2013: 9 · 2012: 11
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- somatic mutations, COSMIC, oncogenes, tumor suppressor, co-occurring mutations, pathway signatures, Ras signaling, Wnt signaling
- MeSH terms
- Cell Cycle, Humans, Models, Genetic, Mutation, Neoplasms, Oncogenes, Organ Specificity, Stress, Physiological, Signal Transduction, Genes, Tumor Suppressor, Databases, Genetic, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
